Evidence map›Paper›PMID 39762450›Full record

ArticleCommunications biology2025

Mucosal-adapted bacteriophages as a preventive strategy for a lethal Pseudomonas aeruginosa challenge in mice.

Luiz Felipe Leomil Coelho, Mateus de Souza Terceti, Sergio Pereira Lima Neto, Raíne Piva Amaral, Ana Luisa Cauvila Dos Santos, William Permagnani Gozzi, Bianca Andrade de Carvalho, Gustavo Aparecido da Cunha, Maria Fernanda Romboli Durante, Lais Sanchietta and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Robust detection in faeces andVeterinary and animal science · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Luiz Felipe Leomil CoelhoVaccine Laboratory, Department of Microbiology and Immunology, Institute of Biomedical Sciences, Federal University of Alfenas, Alfenas, Brazil.
Mateus de Souza TercetiVaccine Laboratory, Department of Microbiology and Immunology, Institute of Biomedical Sciences, Federal University of Alfenas, Alfenas, Brazil.
Sergio Pereira Lima NetoVaccine Laboratory, Department of Microbiology and Immunology, Institute of Biomedical Sciences, Federal University of Alfenas, Alfenas, Brazil.ORCID http://orcid.org/0000-0003-2096-6817
Raíne Piva AmaralVaccine Laboratory, Department of Microbiology and Immunology, Institute of Biomedical Sciences, Federal University of Alfenas, Alfenas, Brazil.ORCID http://orcid.org/0000-0002-3236-3442
Ana Luisa Cauvila Dos SantosVaccine Laboratory, Department of Microbiology and Immunology, Institute of Biomedical Sciences, Federal University of Alfenas, Alfenas, Brazil.
William Permagnani GozziVaccine Laboratory, Department of Microbiology and Immunology, Institute of Biomedical Sciences, Federal University of Alfenas, Alfenas, Brazil.ORCID http://orcid.org/0009-0003-1889-7848
Bianca Andrade de CarvalhoVaccine Laboratory, Department of Microbiology and Immunology, Institute of Biomedical Sciences, Federal University of Alfenas, Alfenas, Brazil.
Gustavo Aparecido da CunhaVaccine Laboratory, Department of Microbiology and Immunology, Institute of Biomedical Sciences, Federal University of Alfenas, Alfenas, Brazil.
Maria Fernanda Romboli DuranteVaccine Laboratory, Department of Microbiology and Immunology, Institute of Biomedical Sciences, Federal University of Alfenas, Alfenas, Brazil.
Lais SanchiettaVaccine Laboratory, Department of Microbiology and Immunology, Institute of Biomedical Sciences, Federal University of Alfenas, Alfenas, Brazil.
Giovana Soares MarangoniVaccine Laboratory, Department of Microbiology and Immunology, Institute of Biomedical Sciences, Federal University of Alfenas, Alfenas, Brazil.
Matheus Luca Carotta GabrielVaccine Laboratory, Department of Microbiology and Immunology, Institute of Biomedical Sciences, Federal University of Alfenas, Alfenas, Brazil.ORCID http://orcid.org/0009-0004-2795-0257
Luiz Cosme Cotta MalaquiasVaccine Laboratory, Department of Microbiology and Immunology, Institute of Biomedical Sciences, Federal University of Alfenas, Alfenas, Brazil.
Eliana Leonor Hurtado CelisInstitute of biotechnology, Sao Paulo State University - UNESP, Sao Paulo, Brazil.ORCID http://orcid.org/0000-0002-9546-1293
Giovanna de Souza ApolinárioInstitute of biotechnology, Sao Paulo State University - UNESP, Sao Paulo, Brazil.ORCID http://orcid.org/0009-0004-9592-6603
João Pessoa Araujo JuniorInstitute of biotechnology, Sao Paulo State University - UNESP, Sao Paulo, Brazil.ORCID http://orcid.org/0000-0002-9153-1485
Carine Ervolino de OliveiraInstitute of Biomedical Sciences, Department of Pathology and Parasitology, Federal University of Alfenas, Alfenas, Brazil.
Victoria Fulgencio QueirozFederal University of Minas Gerais, Institute of Biological Sciences, Department of Microbiology, Belo Horizonte, Minas Gerais, Brazil.
Gabriel Magno de Freitas AlmeidaThe Norwegian College of Fishery Science, Faculty of Biosciences, Fisheries and Economics, UiT-The Arctic University of Norway, Tromsø, Norway. gabriel.d.almeida@uit.no.ORCID http://orcid.org/0000-0003-2317-5092

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pseudomonas aeruginosa is an emergent threat due to the antimicrobial resistance crisis. Bacteriophages (phages) are promising agents for phage therapy approaches against P. aeruginosa. It has been proposed that metazoans harbor phages on their mucosal surfaces, and this could be exploited for the rational design of prophylactic phage therapy. The goal of this study was to evaluate the potential of phage-mucus interaction to prevent infections caused by P. aeruginosa. We isolated two phages capable of infecting P. aeruginosa. Both are similar in morphology and closely related genetically. However, phage VAC3 is more efficient in replicating in mucin-exposed P. aeruginosa in vitro and is preferentially held in the respiratory tract of C57BL/6 mice. Pre-treatment with VAC3 phage protects mice from a lethal dose of P. aeruginosa while VAC1 does not. This shows that phages adapted to mucosal conditions have potential to be applied as prophylactic measures against an ESKAPE pathogen.

Indexed as

Mice, Inbred C57BLPhage TherapyPseudomonas aeruginosaPseudomonas InfectionsAnimalsBacteriophagesFemaleMiceMucous MembranePseudomonas Phages

Identifiers

PMID39762450
PMCPMC11704353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.